Cadrenal Therapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Public

  • Employees
  • 5

Employees

  • Stock Symbol
  • CVKD

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.51
  • (As of Friday Closing)

Cadrenal Therapeutics General Information

Description

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly Angel backed
Corporate Office
  • 822 North A1A
  • Ponte Vedra Beach, FL 32082
  • United States
+1 (904)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 822 North A1A
  • Ponte Vedra Beach, FL 32082
  • United States
+1 (904)

Cadrenal Therapeutics Timeline

2023202420252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cadrenal Therapeutics Stock Performance

As of 13-Nov-2026, Cadrenal Therapeutics’s stock price is $1.51. Its current market cap is $5.39M with 3.57M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.51 $1.51 $0.82 - $12.50 $5.39M 3.57M 479K -$4.91

Cadrenal Therapeutics Financials Summary

As of 30-Jun-2026, Cadrenal Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 7,973 11,992 21,467 553
Revenue 0 0 0 0
EBITDA (11,652) (13,454) (10,959) (8,587)
Net Income (11,544) (13,237) (10,651) (8,357)
Total Assets 5,589 4,327 10,124 8,519
Total Debt 0 0 0 21
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cadrenal Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cadrenal Therapeutics‘s full profile, request access.

Request a free trial

Cadrenal Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immun
Drug Discovery
Ponte Vedra Beach, FL
5 As of 2025

San Diego, CA
 

Minneapolis, MN
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cadrenal Therapeutics Competitors (4)

One of Cadrenal Therapeutics’s 4 competitors is Arthrosi Therapeutics, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arthrosi Therapeutics Formerly VC-backed San Diego, CA
DiaMedica Therapeutics Formerly VC-backed Minneapolis, MN
Ardelyx Formerly VC-backed Waltham, MA
Akebia Therapeutics Formerly VC-backed Cambridge, MA
To view Cadrenal Therapeutics’s complete competitors history, request access »

Cadrenal Therapeutics Patents

Cadrenal Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025245618-A1 Methods for treating heparin-induced thrombocytopenia Pending 27-Mar-2024
AU-2025229087-A1 Method for preventing coagulation in patients with implanted cardiac devices Pending 01-Mar-2024
US-20250276120-A1 Method for preventing coagulation in patients with implanted cardiac devices Pending 01-Mar-2024
WO-2025184627-A1 Method for preventing coagulation in patients with implanted cardiac devices Pending 01-Mar-2024
US-20260048071-A1 12-lipoxygenase inhibitors for the treatment of lupus Pending 11-Nov-2022 A61K31/63
To view Cadrenal Therapeutics’s complete patent history, request access »

Cadrenal Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cadrenal Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cadrenal Therapeutics‘s full profile, request access.

Request a free trial

Cadrenal Therapeutics Investments & Acquisitions (2)

Cadrenal Therapeutics’s most recent deal was a Corporate Asset Purchase with Veralox Therapeutics (VLX-1005 and 12-Lipoxygenase Assets in Frederick, Maryland) for . The deal was made on 11-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Veralox Therapeutics (VLX-1005 and 12-Lipoxygenase Assets in Frederick, Maryland) 11-Dec-2025 Corporate Asset Purchase Buildings and Property
eXIthera Pharmaceuticals 15-Sep-2025 Merger/Acquisition Drug Discovery
To view Cadrenal Therapeutics’s complete investments and acquisitions history, request access »

Cadrenal Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

38.59 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Cadrenal Therapeutics’s complete esg history, request access »

Cadrenal Therapeutics FAQs

  • When was Cadrenal Therapeutics founded?

    Cadrenal Therapeutics was founded in 2022.

  • Where is Cadrenal Therapeutics headquartered?

    Cadrenal Therapeutics is headquartered in Ponte Vedra Beach, FL.

  • What is the size of Cadrenal Therapeutics?

    Cadrenal Therapeutics has 5 total employees.

  • What industry is Cadrenal Therapeutics in?

    Cadrenal Therapeutics’s primary industry is Drug Discovery.

  • Is Cadrenal Therapeutics a private or public company?

    Cadrenal Therapeutics is a Public company.

  • What is Cadrenal Therapeutics’s stock symbol?

    The ticker symbol for Cadrenal Therapeutics is CVKD.

  • What is the current stock price of Cadrenal Therapeutics?

    As of 13-Nov-2026 the stock price of Cadrenal Therapeutics is $1.51.

  • What is the current market cap of Cadrenal Therapeutics?

    The current market capitalization of Cadrenal Therapeutics is $5.39M.

  • Who are Cadrenal Therapeutics’s competitors?

    Arthrosi Therapeutics, DiaMedica Therapeutics, Ardelyx, and Akebia Therapeutics are competitors of Cadrenal Therapeutics.

  • What is Cadrenal Therapeutics’s annual earnings per share (EPS)?

    Cadrenal Therapeutics’s EPS for 12 months was -$4.91.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process